



MAYNE PHARMA CLOSES TRANSACTION WITH NOVAN AND EPI HEALTH FOR RHOFADÉ®

- Adds a single source, accretive asset to portfolio of dermatology products
- Aligns with Company mission of expanding access to high quality medicines

26 September 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the completion of the transaction announced on September 4, to acquire the global rights to RHOFADÉ® from Novan, Inc. and EPI Health, LLC. RHOFADÉ® (oxymetazoline hydrochloride) cream 1%. RHOFADÉ® is manufactured pursuant to NDA 208552 and is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. Under the terms of the agreement, Mayne Pharma has paid US\$8M plus associated cure costs of US\$1.2M.

Mayne Pharma expects to launch RHOFADÉ® in early October.

Mayne Pharma's CEO Mr Shawn Patrick O'Brien said: "RHOFADÉ® fits well with our other products that help patients suffering from rosacea. We are pleased with the court's approval of the deal and happy with our ability to close quickly and within our projected deal terms."

For further information contact:

Australia:

Craig Haskins

+61 421 029 843

ir@maynepharma.com

USA:

Lisa M. Wilson

+1 917-543-9932

ir@maynepharma.com

Authorised for release to the ASX by the Chair

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

RHOFADÉ is a registered trademark of EPI Health, LLC.